Uroplasty Plans to Double Sales Force During F...(ating results; the impactof technologica...),Health

Date:4/3/2008

ating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, our historical reliance on a single product for most of our current sales; our ability to commercialize our recently licensed product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of clinical trials; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price. We cannot assure that we can successfully retain and expand in our projected timeframe, or at all, our U.S. field sales force, that any new sales representatives we hire will profitably generate sales in our projected timeframe, or at all, that our active customer base will continue to grow or that we will be successful in helping our active customers introduce, and our existing customers will continue to market, our Urgent PC technology. Our fiscal 2008 to date financial performance is not indicative of future performance. We cannot assure that we will achieve our projected revenue target range or revenue growth for fiscal 2008 or 2009. We further cannot assure that we will have the capital resources necessary to achieve our fiscal 2009 business and financial objectives. Uroplasty undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. O
'/>"/>

SOURCE Uroplasty, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
2. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
3. Uroplasty Expands Marketing Program for Urology Practices
4. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
5. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
6. Uroplasty to Host Second Quarter Conference Call on November 1
7. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
8. STAAR Surgical Plans Major Presence at ASCRS
9. Medicare Advantage Plans Have New, Better Way to Access CMS Data
10. Ohio Association of Health Plans Announces New Officers
11. Community First Health Plans Selects TCS Healthcare Technologies Care Management Software System